Chemotherapy News and Research

Latest Chemotherapy News and Research

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).

19 Oct 2010

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

Amgen will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today's meeting of the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC).

19 Oct 2010

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.

19 Oct 2010

Researchers identify new mechanism that could help develop effective chemotherapy drug

Information on proteins is critical for understanding how cells function in health and disease. But while regular proteins are easy to extract and study, it is far more difficult to gather information about membrane proteins, which are responsible for exchanging elements essential to our health, like copper, between a cell and its surrounding tissues.

19 Oct 2010

Medifocus receives two patents to expand IP portfolio

Medifocus, Inc. is pleased to announce that it has recently received notice of allowances for two additional international patents to expand its extensive Intellectual Properties (IP) portfolio in addition to the patents Medifocus has exclusively licensed from the Massachusetts Institute of Technology (MIT).

19 Oct 2010

NCCN updates Clinical Practice Guidelines for Breast Cancer

The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Breast Cancer to affirm the recommendation regarding the use of bevacizumab (Avastin®, Genentech/Roche) in the treatment of metastatic breast cancer.

19 Oct 2010

Karmanos Cancer Institute awarded $3M NIH grant to study triple-negative breast cancer

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit have received a nearly $3 million, five-year research project (RO1) grant from the National Institutes of Health to study a potentially ground-breaking immunotherapy treatment for women with one of the deadliest forms of breast cancer – triple-negative breast cancer. The research is exclusive to the Karmanos Cancer Institute.

19 Oct 2010

Study quantifies impact of screening programs in pre-Medicare population

Investment in screening programs that target the pre-Medicare population, individuals aged between 50 and 64, is needed to reduce the costs of colorectal cancer in the Medicare program, according to the results of a new study, "Cost-Savings to Medicare from Increased Colorectal Cancer Screening in the Pre-Medicare Population," unveiled today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.

19 Oct 2010

New clinical trial to treat brain cancer launched

Cancer Research UK and Cancer Research Technology the charity's development and commercialisation arm together with immatics biotechnologies have launched the first clinical trial of a promising cancer vaccine to treat glioblastoma, one of the most common forms of brain cancer.

19 Oct 2010

AACR's magazine gives details about immense challenges faced by homeless cancer patients

An article published in the fall 2010 issue of CR, the AACR's magazine for cancer survivors and their families and caregivers, details the immense challenges faced by those who suffer with cancer and lack the necessary resources for proper treatment and care the homeless.

18 Oct 2010

St. Joseph's gynecologic oncologist expresses concern about ovarian cancer study

An internationally-recognized gynecologic oncologist at St. Joseph's Hospital and Medical Center in Phoenix, Arizona is warning that the results from a long-awaited global study of ovarian cancer should be viewed cautiously.

18 Oct 2010

Celgene acquires Abraxis BioScience

Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.

18 Oct 2010

Access receives first MuGard prescriptions and reimbursement

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.

15 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

A new therapeutic approach for cancer

Trials are being organized for a new therapeutic approach to treating cancer, under exclusive license by Viral Genetics, Inc. According to Scott & White Healthcare Senior Vice President for Research Richard E. Beswick, M.D., who is also assistant dean of research at the Texas A&M Health Science Center College of Medicine, the trials will be conducted at the Glenda Tanner Vasicek Cancer Treatment Center, located at Scott & White in Temple, Texas.

15 Oct 2010

Delcath executes melphalan supply agreement with Synerx and Bioniche Teoranta

Delcath Systems, Inc. announced today that it has executed a multi-year supply agreement with Synerx Pharma, LLC and Bioniche Teoranta, an affiliate of Mylan, Inc., for the supply of Delcath's branded melphalan hydrochloride for injection ("melphalan"). Melphalan is the chemotherapeutic drug used with Delcath's Chemosaturation system in its Phase III clinical study for the treatment of patients with hepatic metastases from ocular or cutaneous melanoma.

15 Oct 2010

Caris Life Sciences presents new diagnostic data at ACG 2010

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic technologies, today announced upcoming highlights from the Company's presentations at the 2010 Annual Meeting of the American College of Gastroenterology ("ACG 2010") held in San Antonio, TX, October 15-20. In total, Caris was awarded 17 accepted abstracts, three of which are ACG Presidential Poster Award recipients.

15 Oct 2010

MRI-guided laser ablation offers way to kill tumors

Physicians at Mayo Clinic's Florida campus are among the first in the nation to use a technique known as MRI-guided laser ablation to heat up and destroy kidney and liver tumors. So far, five patients have been successfully treated meaning no visible tumors remained after the procedure.

15 Oct 2010

Applied Skin Technology launches three revolutionary products for skin damage

Applied Skin Technology announces the launch of three breakthrough moisturizers, harnessing cutting-edge skin care technology, and using the most effective skin restoring ingredients available. These revolutionary products are formulated for three different categories: women, men, and a recovery cream for skin that has been damaged due to a medical condition or the side effect of medical treatment.

15 Oct 2010

Costs for end-of-life care rising, hospice care may be an antidote

Health care costs at the end of life show no signs of leveling off, according to new research from the United States and Canada published in the Archives of Internal Medicine.

15 Oct 2010